Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
253 hedge funds and large institutions have $6.92B invested in Acceleron Pharma in 2020 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 82 increasing their positions, 85 reducing their positions, and 27 closing their positions.
63% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 27
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
14% more capital invested
Capital invested by funds: $6.08B → $6.92B (+$841M)
6% more funds holding
Funds holding: 238 → 253 (+15)
4% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 85
19% less call options, than puts
Call options by funds: $19.6M | Put options by funds: $24.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$44.7M |
| 2 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$41.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.7M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$35.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$136M |
| 2 |
O
OrbiMed
New York
|
-$67.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$42.3M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$31.8M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$26.9M |
XLRN Hedge Fund Activity: Q4 2020 in Review
253 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2020, worth a combined $6.92B — up 14% from $6.08B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new XLRN positions and 27 closed out — a net gain of 17 holders — while 82 added to existing stakes and 85 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $44.7M. The largest seller was Fidelity Investments, cutting an estimated $136M.
- 253 institutional investors held Acceleron Pharma (XLRN) as of Q4 2020, up from 238 in Q3 2020.
- Funds reported $6.92B of Acceleron Pharma stock for Q4 2020, up 14% quarter-over-quarter.
- 44 funds opened new Acceleron Pharma positions in Q4 2020 and 27 closed out, a net change of +17 holders.
- The largest Acceleron Pharma buyer in Q4 2020 was Citadel Advisors, an estimated $44.7M added.
- The largest Acceleron Pharma seller in Q4 2020 was Fidelity Investments, an estimated $136M sold.
Based on aggregated 13F filings for Q4 2020.